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Accurately measuring the complex motor behaviors of the
gastrointestinal tract has tremendous value for the under-
standing, diagnosis, and treatment of digestive diseases. This
review synthesizes the literature regarding current tests
that are used in both human beings and animals. Further
opportunity remains to enhance such tests, especially when
such tests are able to provide value in both the preclinical
and the clinical settings.
The ability to assess the complex motor functions of the
gastrointestinal tract accurately has been of tremendous
value to understanding and treating digestive diseases.
Unlike other smooth or cardiac muscle organ systems
with relatively more rhythmic and patterned motor
behavior, the complexity of the diverse motor behaviors of
the alimentary canal have made the development and use
of clinical and preclinical tests of gastrointestinal motor
function a great challenge. It is perhaps this complexity, as
well as the importance of gastrointestinal function to
overall health and well-being, that have fascinated early
physiologists and continue to push modern physiologists
and clinical diagnosticians to develop new and more ac-
curate measurements of motility. It is also because of this
complexity that the standardization of these measures
presents hurdles to broad adoption and that the mea-
surements of the more complex motility functions remain
restricted mainly to tertiary referral centers. (Cell Mol
Gastroenterol Hepatol 2016;2:412–428; http://dx.doi.org/
10.1016/j.jcmgh.2016.04.003)
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nostic value in stratifying patients who present with a
relatively limited repertoire of symptoms in the complex
multifactorial digestive diseases into more manageable
subsets and in the identiﬁcation of underlying pathophys-
iology. Second, these clinical tests provide measures that
can be used to objectively determine the efﬁcacy of ther-
apies for digestive diseases in the clinic and during drug
and device development in clinical trials. Third, motility
measurements in human beings have value in broadeningour understanding of the physiology and pathophysiology
of the gastrointestinal tract to generate new hypotheses
and new drug targets to understand and treat digestive
diseases.
Motility tests in nonhuman animals also have value
that parallels the value of tests for human beings. First,
animals serving as companions, or in labor, sports, and
food production industries, beneﬁt from the diagnostic
value of accurate motility tests in veterinary medicine.
Second, motility tests provide the basis for objective
measures to assess the efﬁcacy and dosing guidelines of
new therapies in preclinical drug and device development.
Third, animal models provide the basis for understanding
the physiology and pathophysiology of the gastrointestinal
tract. This latter value historically has been greater in
nonhuman animals because of the ability to conduct
terminal or ex vivo experiments followed by anatomic or
biochemical assessments that are not possible in human
beings.
The purpose of this review is to critically assess the
current state of motility tests (listed in Table 1, and
examples given in Figure 1), based on these values in
both human beings and non–human beings. It is organized
by region of the alimentary canal in an oral to anal direc-
tion, followed by measures of whole-gut transit. The hope
is that such juxtaposition of human and nonhuman tests
will enlighten both the beneﬁt and deﬁciencies in each
to aid in the de novo or cross-development of new
motility tests.
In the interest of brevity, we will not describe tests of
esophageal motility here. High-resolution manometry has
become the diagnostic tool of choice, about which many
recent reviews have been published.1–3
Table 1.Tests Currently Available for Measuring Gastrointestinal and Colonic Motility
Function Tests available
Gastric capacity or accommodation Barostat balloon measurements
Nutrient drink test
SPECT
Ultrasonography
MRI
High-resolution intragastric manometry
Gastric emptying Scintigraphy
Wireless pH and motility capsule
Stable isotope breath tests
Gastric transit in preclinical studies Analysis of gastric contents
Stable isotope breath tests
Scintigraphy
Small-bowel transit Breath hydrogen tests
Stable isotope breath tests
Scintigraphy
Wireless pH and motility capsule
Whole-gut transit in preclinical studies Nonabsorbable marker such as carmine red
Scintigraphy using steel beads and barium in mice
Colonic transit Radiopaque markers
Scintigraphy
Wireless pH and motility capsule
Gastrointestinal, colonic, and anorectal contractility Antropyloroduodenal manometry
Wireless pH and motility capsule
Colonic phasic contractility (including high-resolution manometry) and tone
Anorectal manometry
Colonic motility and transit in preclinical studies Bead expulsion
Colonic manometry (including high-resolution manometry)
Scintigraphy
New MRI applications All the earlier-described functions as well as anorectal and pelvic ﬂoor motion and
anatomic integrity
NOTE. Tests with the strongest validation or most widely available and used are indicated in italics.
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and Accommodation
One of the principal functions of the proximal stomach is
the storage of ingested food. The gastric fundus and body
are able to accommodate large volume changes, while
maintaining a relatively low intragastric pressure. Altered
gastric tone and distensibility may occur in several disease
states, including tumor inﬁltration, vagal dysfunction, and
post–gastric surgery status, and in up to 40% of patients
with functional dyspepsia.4Barostat Balloon Measurements
The gold standard for the measurement of tone in hollow
organs was the barostat,5 which estimates changes in tone
by the change of volume of air in an inﬁnitely (typically
polyethylene) compliant balloon maintained at a constant
pressure to maintain the balloon in apposition with the
stomach lining. The barostat maintains the constant pres-
sure by infusion or aspiration of air in response to relaxa-
tion or contraction of stomach tone. This method is not used
extensively in clinical practice because it requires intubation
and results in stress and discomfort during the tests, which
may last 3 hours or longer.6Development and validation studies of the barostat to
measure compliance, tone, and postprandial accommoda-
tion in the dog were performed by Azpiroz and Malagelada.5
Since then, the barostat has been used extensively in ani-
mals including cats,7 rabbits,8 pigs,9 horses,10 rats,8,11 and
mice.12Satiation or Nutrient Drink Test
The nutrient drink test has been proposed as a surrogate
method for estimating gastric volumes. In this test, a stan-
dardized liquid nutrient drink, such as Ensure (1 kcal/mL;
Ross Products, Division of Abbott Laboratories, Columbus,
OH), is ingested at a standard rate of 30 mL/min, and the
volume to normal fullness and the maximum tolerated
volume are recorded as measures of satiation. Postprandial
symptoms of nausea, fullness, bloating, and pain are
measured 30 minutes after the meal.13 Tack et al14 sug-
gested that a high-caloric, slowly administered drinking test
compared favorably with the barostat in predicting
impaired gastric accommodation, especially in patients with
a maximum tolerated volume less than 750 kcal. Because of
the obvious limitations of feedback regarding sensory ex-
periences, there are no reports of the use of nutrient drink
tests in nonhuman animals.
Figure 1. Examples of the wide range of motility measurements available for human studies: stable isotope breath test,
scintigraphic transit, intraluminal manometry by perfused manometers or strain gauges on tubes or wireless capsules,
and measurement of gastric capacity and accommodation by SPECT or high-resolution manometry.
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Single-photon emission computed tomography (SPECT)
imaging has been validated extensively in vitro and in vivo
for the measurement of gastric volumes during fasting and
postprandially in human beings, including comparison with
the barostat.15–17 After intravenous administration of 10 mCi
technetium-99m (99mTc)-pertechnetate, a substrate for the
sodium/iodide symporter that is accumulated and secreted
into the lumen by parietal and mucin-secreting cells of the
gastric mucosa, tomographic images of the stomach are ac-
quired using a large ﬁeld-of-view, dual-headed gamma
camera, with the patient in a supine position. From the
transaxial images of the stomach, 3-dimensional images are
reconstructed using a commercially available software anal-
ysis program that is used for other 3-dimensional volume
rendering with transaxial imaging (eg, computed tomogra-
phy [CT], magnetic resonance imaging [MRI]) and total
gastric volume is measured during fasting and during theﬁrst 10 minutes after a standard liquid nutrient meal (300
mL Ensure). This allows reconstruction of the stomach based
on the location of the mucosal layer, and the estimated vol-
ume serves as a surrogate for the internal volume of the
stomach. SPECT shows the effects of disease on post-meal
gastric accommodation and effects of medications such as
nitrates, erythromycin, glucagon-like peptide-1, and octreo-
tide18,19 in health and diseases such as diabetes, fundopli-
cation, and functional dyspepsia.20,21
Intraindividual and interindividual coefﬁcients of vari-
ance in postprandial and accommodation volumes by SPECT
were not signiﬁcantly different and ranged from 16% to
22%.22 The effects of liquid and solid equicaloric meals on
gastric volumes have been described, and measurements of
gastric volume with the same caloric liquid meal an average
of 9 months apart showed a coefﬁcient of variation of 10%.23
It also is possible to measure gastric emptying and vol-
ume simultaneously.24,25 The noninvasive nature of the
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Clinic in research and practice, especially in suspected dis-
orders of gastric accommodation such as dyspepsia. How-
ever, the test involves radiation exposure, and SPECT
equipment and the 3-dimensional reconstruction and vol-
ume rendering are not widely available. Another potential
pitfall is that the resolution of the imaging does not equal
that of CT or MRI.
Application in animal studies. Although NanoSPECT-CT
(Mediso Medical Imaging Systems, Budapest, Hungary) of
gavaged technetium-labeled activated charcoal diethylene
triaminepentaacetic acid has been used to assess gastroin-
testinal transit in mice,26 to our knowledge SPECT imaging
has not been used to assess gastric accommodation specif-
ically in nonhuman animals. Given the rapidly advancing use
of 99mTc-pertechnetate and other sodium/iodide symporter
substrates in numerous animal models27,28 as well as de-
scriptions of methods to circumvent the high stomach signal
that confounds such studies,29 it is reasonable to assume
that this well-validated approach to assess gastric accom-
modation in human beings can be reverse-translated easily
for use in preclinical studies.
Ultrasonography
Imaging-basedmethods tomeasure gastric volume include
3-dimensional reconstruction of images acquired by ordinary
ultrasonography assisted bymagnetic scan-head tracking.30,31
Thus, an outline of the total stomach volume visualized after
ingestion of a liquidmeal (that serves as a contrast medium)32
has been applied in adolescents and compared with simulta-
neously measured gastric volumes by SPECT.33
Magnetic Resonance Imaging
The ﬁrst application of MRI using a spin-echo T1-
weighted imaging sequence addressed the volume of the
stomach during fasting, but not in the postprandial period.34
Volumes measured with MRI and barostat differ signiﬁ-
cantly because the barostat measures only the proximal
stomach, whereas MRI records the entire stomach volume;
however, there was a statistically signiﬁcant correlation
between the 2 methods, and MRI also was able to show
volume effects induced by glucagon (increase) and eryth-
romycin (decrease).
MRI, using 3-dimensional gradient-echo and 2-
dimensional half-Fourier acquisition single-shot turbo spin
echo sequences,35 has been used to measure postprandial
gastric volume change, which exceeded the ingested meal
volume by 106 ± 12 mL (SEM). The advantage of MRI over
SPECT is the ability to distinguish air from ﬂuid under
fasting and postprandial conditions, respectively. MRI also
has shown that the postprandial volume excess mainly
comprised air (61 ± 5 mL), which was not signiﬁcantly
different when the volume ingested was ingested in 30- or
150-mL aliquots. Fasting and postprandial gastric volumes
measured by MRI generally were reproducible within sub-
jects. Gastric volumes measured by SPECT were higher than
MRI, reﬂecting the fact that SPECT reconstruction includes
the volume occupied by the imaged gastric wall. AlthoughMRI has many advantages, including a lack of radiation
exposure, it is not widely used to measure gastric accom-
modation in clinical practice or research.
High-Resolution Intragastric Manometry
By using a high-resolution manometry catheter, which
typically is used for esophageal motility measurements,
Janssen et al36 showed that, during nutrient drink ingestion,
there is a reduction in intraluminal pressure that provides a
less-invasive alternative to the barostat for the assessment
of gastric accommodation. The method also has been used
to show pharmacologic effects, such as with peppermint
oil37 and liraglutide.38
Gastrointestinal and Colonic Transit
Gastric Emptying
Scintigraphy. Gamma camera scintigraphy is the most
widely used test for the assessment of gastric motility; it
provides a direct, noninvasive quantiﬁcation of gastric
emptying.39 A simpliﬁed protocol with imaging at 1, 2, and 4
hours with a standard meal was ﬁrst proposed at the Mayo
Clinic,40 and a variation subsequently was validated in a
large multinational study in 123 subjects41 and was adopted
by the American Neurogastroenterology and Motility Soci-
ety and the Society of Nuclear Medicine.42 A standard, 2%
fat meal consisted of 4 ounces of Eggbeaters (Conagra
Foods, Omaha, NE) or equivalent egg white substitute, 2
slices of bread, strawberry jam (30 g), and 120 mL water
(total 240 kcal) and was radiolabeled with 0.5–1 mCi 99mTc-
sulfur colloid. This is a relatively small meal, which may not
reliably induce symptoms in patients with functional
dyspepsia, although it is useful for diagnosing gastroparesis.
The Mayo Clinic method uses 2 natural eggs and contains
30% of the calories as fat (total, 320 kcal). The test meal
determines the rate of emptying,43 and normal values are
essential for interpretation of the test when performed
clinically; thus, Mayo Clinic published data from 319 healthy
controls.44 There is signiﬁcant intraindividual variation in
gastric emptying rates of 12%–15%, even in healthy in-
dividuals.44,45 The performance characteristics of the 30%
fat, 320-kcal meal have been documented.44
The main indications for use of this test are the inves-
tigation of unexplained nausea, vomiting, and dyspeptic
symptoms; screening for impaired gastric emptying in dia-
betic patients being considered for incretin treatment to
enhance glycemic control (eg, pramlintide and GLP-1 ago-
nists); and assessment of patients with suspected diffuse
gastrointestinal motility disorder in combination with small-
bowel and colonic transit.
In human research, the gastric emptying test is used to
understand the pathophysiology of symptoms or in the
development of pharmacologic agents. There is a vast
amount of literature on the use of radioscintigraphy to
measure gastric emptying in large animals. The ﬁrst appli-
cation documented the effects of vagotomy and carbachol on
gastric emptying in dogs.46
Wireless pH and motility capsule. These nondigestible
wireless capsules can measure pH, pressure, and
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abrupt change in pH from the gastric acidic milieu to the
almost alkaline duodenum usually is associated with antral
phasic contractions of the migrating motor complex (MMC),
and it signals that the capsule has left the stomach.47 When
taken with a meal, the capsule generally empties from the
stomach after liquids and triturable solids have emptied,
usually with phase III of the MMC or, in approximately one
third of cases, with high-amplitude antral contractions.48
Patients ingest the capsule with a standard meal and,
from 6 hours after capsule ingestion, patients can engage in
normal daily activity, including ad libitum feeding. The
wireless capsule acquires data continuously for up to 5
days, and this permits calculation of gastric, small-bowel,
colon, and whole-gut transit. These wireless capsules also
measure intraluminal pressure. In validation studies con-
ducted with simultaneous gastric emptying by scintigraphy
in healthy subjects and patients with gastroparesis,49 the
gastric emptying time for the capsule and the scintigraphic
gastric emptying time at 4 hours were correlated signiﬁ-
cantly (r ¼ 0.73), and the capsule discriminated between
normal or delayed gastric emptying with a sensitivity of
0.87 at a speciﬁcity of 0.92.49 The advantages of the motility
capsule are that the study can be conducted anywhere, there
is a lack of radioactivity, and it has an ability to determine
small-bowel, colon, and whole-gut transit times, as well as
contractility.50–52 The wireless motility capsule also is
capable of identifying the effects of pharmacologic agents on
gastric contractility.53
Stable isotope breath tests. These tests evaluate gastric
emptying noninvasively and without radiation hazard. The
carbon-13 (13C) isotope can be incorporated into compo-
nents of a solid meal (eg, the medium-chain fatty acid,
octanoic acid, or the blue-green algae, Spirulina platensis) or
in a liquid meal (13C-acetate) to assess gastric emptying of
liquids. After ingestion, the solid meal is triturated and
emptied by the stomach, digested, and absorbed in the
proximal small intestine, metabolized by the liver, and 13CO2
is excreted by the lungs, resulting in an increase in expired
13CO2 over baseline. The test and breath sample collection
can occur at the point of care. The rate-limiting step in 13CO2
excretion is gastric emptying of the meal.
In studies comparing the 13C gastric emptying breath
test (GEBT) performed simultaneously with scintigraphy,
the GEBT provided accurate assessment of the gastric
emptying of solids with a coefﬁcient of variation comparable
with scintigraphy.45 In addition, the 13C-spirulina GEBT
documented accelerated or delayed gastric emptying
induced with erythromycin or atropine, respectively.54 The
13C-spirulina GEBT was approved by the Food and Drug
Administration in 201555 based on a clinical study using
data from 115 participants who typically would have un-
dergone a gastric emptying test, showing that the GEBT
results agreed with the scintigraphy results 73%–97% of
the time when measured at various time points during
the test.56 Pitfalls included a potential loss of accuracy in
patients with diseases involving the intestinal mucosa,
pancreas, liver, and respiratory system.Gastric Emptying Studies in Nonhuman Animals
Acute gastric emptying study by analysis of gastric
contents. The long history and vast number of physiolog-
ical and preclinical drug development studies using timed
end point analysis of gastric contents after gavage or
ingestion of a labeled or visually detectable and quantiﬁ-
able meal to study gastric emptying are too numerous to
reproduce in this short review. The approach is precise and
inexpensive because, rather than relying on indirect mea-
surements, the percentage of the meal remaining in the
stomach can be calculated directly. Therefore, the approach
remains the standard by which preclinical validation
studies of novel tests of gastric emptying are compared.
Relatively recent advancements in this approach have been
the development of new tracers to increase the sensitivity
of labeled meal detection as well as the detection of the
labeled meal throughout the gastrointestinal tract to assess
overall transit as measured by the geometric center,57,58
rather than the percentage emptied or leading edge.
These new tests that deﬁne the geometric center and
segment distribution also can be used to study whole-gut
transit.
Longitudinal gastric emptying studies. The advent of
longitudinal studies in mice that required repeated mea-
sures of gastric emptying during disease development or
therapy has led to the use of gastric emptying tests devel-
oped for human beings in preclinical models. In these
studies, the need for noninvasive repeatable measures
outweighs the relatively low interindividual variability and
cost of end point studies. These tests include scintig-
raphy59,60 and the 13C-octanoic acid GEBT.61,62 The
13C-octanoic acid GEBT also has been validated for mea-
surement of gastric emptying in horses,63,64 cattle,65
dogs,66,67 and rats.68 In addition, in nonobese diabetic
mice, a model of type 1 diabetes, the expected effects of
bethanechol and atropine were shown.62 These gastric
emptying tests developed in human beings and now used
routinely in preclinical studies, which can be translated
directly into clinical trials, are the clearest example of the
beneﬁt of the bedside-to-bench-to-bedside approach, and
should serve as a model for other motility tests that are
presented in this review.
Gamma camera scintigraphy has been validated for use
in small animals; thus, awake mice were accustomed to light
restraint and to eating cooked egg white (0 g fat), whole egg
(0.10 g fat/g), or egg yolk (0.31 g fat/g). Gastric emptying of
each diet was measured by labeling the test meals with
99mTc-mebrofenin and using a conventional gamma camera
equipped with a high-resolution, parallel-hole collimator.
This method has been used to document the effects of
devazepide (a cholecystokinin-A–receptor antagonist)60
botulinum toxin injection into the antral wall in knockout
animals and in pharmacologic modulation,69,70 and the role
of inﬂammation and novel therapies for postoperative ileus
in animal models.71,72
Recent advances in ultrasound research in nonhuman
animals have suggested that clinical tests using this nonin-
vasive approach soon may be in development.73,74
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Breath Hydrogen Tests
The breath test is based on the presumption that the
hydrogen excreted in the breath is the product of colonic
bacterial fermentation of unabsorbed carbohydrates inges-
ted orally. Lactulose is the most widely used carbohydrate
substrate for orocecal transit time determination because
the time lag between ingestion of lactulose and the increase
in breath hydrogen is at least 3, 5, or 10 parts per million
above baseline. There is a high degree of correlation with
simultaneous liquid transit by scintigraphy,75–78 and the
test documents pharmacologic effects on gut motility.79–83
Unfortunately, lactulose itself markedly accelerates transit,
presumably owing to its osmotic activity. In addition, these
tests usually are conducted during fasting, and this may not
accurately reﬂect postprandial small-bowel transit, and,
usually, symptoms occur postprandially.
Stable Isotope Breath Test
A stable isotope (lactose 13C-ureide) was proposed with
a very small dose of the substrate (0.5–1.2 g), which cannot
be cleaved at the human intestinal brush border and re-
quires the colonic bacterial ﬂora to free 13C-ureide, which
subsequently undergoes hydrolysis with release of 13CO2
and excretion by the lungs. The ratio of breath 13CO2/
12CO2
is determined by isotope ratio mass spectrometry, and the
ﬁrst increase in breath at 2.5 SDs greater than the running
average indicates the orocecal transit time.84 The lactose
13C-ureide test has been validated by comparison with
scintigraphy84 and has been used to evaluate the effects of
pharmacologic agents.85–87
Small-Intestine Scintigraphy
Small-bowel scintigraphy is not used commonly outside
of research as part of whole-gut transit tests.88 Small-bowel
transit time can be calculated as the time for 10% or 50% of
the radiolabel to arrive at the terminal ileum or cecum, after
correcting for gastric emptying by subtracting the time for
the equivalent proportion emptied from the stomach.89 A
valid surrogate for the 10% scintigraphic small-bowel
transit time is the percentage of the meal ﬁlling the colon
at 6 hours (CF6), which reﬂects orocecal transit.40 Because
the radiolabel is ingested with the meal, the result is
impacted signiﬁcantly by the rate of gastric emptying.
The range of normal values for colonic ﬁlling at 6 hours is
11%–70% with radiolabeled nondigestible particles,90,91 or
43%–95% for radiolabeled digestible solids.92 However,
more recent studies conducted in more than 200 healthy
controls have shown that variation in CF6 in healthy sub-
jects is 0%–100% and, therefore, it is not possible to deﬁ-
nitely diagnose abnormal small-bowel motility using CF6
(Camilleri, unpublished data). In clinical practice, a low
value (eg, <20%) of CF6 often is associated with slow
colonic transit, particularly in the right colon, and it is un-
clear whether this is a reﬂection of signiﬁcant pathology in
the small intestine or is simply a consequence of failed
ascending colon emptying preventing the ﬂow of the ileal
content into the colon.In research, these measurements of small-bowel transit
time have shown the effects of treatment, such as
cisapride in gastroparesis and chronic intestinal dysmo-
tility,93,94 tegaserod in irritable bowel syndrome with con-
stipation,95 or prucalopride and YKP10811 in functional
constipation.96,97
First CT enterography and now MR enterography have
become routine diagnostic tools for inﬂammatory bowel
disease,98,99 and it is of great interest that these tests include
dynamic image sets to assess motility in affected bowel seg-
ments.100 Perhaps the routine collection of large data sets can
be used to develop better automated image analyses and
more robust small-bowel imaging for motility disorders in-
dependent of organic disease. Indeed, a very recent study
used the automated motility assessment of MR enterography
developed for patients with Crohn’s disease to assess small-
bowel motility in patients with chronic intestinal pseudo-
obstruction,101 showing the potential of such an approach.Use of Wireless pH and Motility Capsule
to Measure Small-Bowel Transit
Small-bowel transit time also can be measured with a
wireless motility capsule (WMC).49 The transit of large
indigestible solids depends on the phase II and phase III
activity of the interdigestive motor complex,102 as well as
fed intestinal motility, but the evidence is limited. The
procedure is similar to that for WMC measurement of
gastric emptying. The WMC small-bowel transit time is
deﬁned as the interval between this increase in pH and the
time when the pH suddenly decreases by more than 1 U for
at least 5 minutes as the WMC enters the cecum.
In separate studies in 9 healthy subjects, the median
WMC small-bowel transit time was 350 minutes (inter-
quartile range [IQR], 169–676 min),103 276 minutes (IQR,
240–354 min),104 and 234 minutes (IQR, 201–293 min).105
A practical disadvantage of the test is occasional difﬁculty in
identifying the 1-U pH decrease signifying passage into the
cecum, especially in patients with postsurgical changes (eg,
right hemicolectomy) or incompetent ileocecal valve
resulting in bacterial colonization of the distal ileum. The
nondigestible, 26  13 mm WMC may become impacted in
the gastrointestinal tract; therefore, contraindications
include suspected mechanical obstruction, recent gastroin-
testinal surgery (within 3 months), and Crohn’s disease.Whole-Gut Transit in Preclinical Models
Whole-gut transit in mice typically is studied by the oral
administration of a nonabsorbable marker such as carmine
red and subsequent monitoring for the ﬁrst appearance of
the marker in stool.106,107 Obviously, this test is an assay of
the leading edge of the content within the digestive tract
that may simplify or misrepresent the overall motility of the
gastrointestinal tract. Terminal experiments, in which the
orally administered tracers are assayed in numerous seg-
ments of the gastrointestinal tract to assess overall transit
as measured by the geometric center,57,58 improve the
limitations of leading edge experiments such as carmine red,
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repeatable, tests of whole-gut transit.
A recent study described scintigraphy using steel beads
and barium in mice to measure intestinal transit in a
nonterminal manner.108 This is an intriguing development
that may lead to better noninvasive preclinical studies;
however, the relatively poor accuracy of clinical scintig-
raphy for intestinal transit, as presented earlier, may limit
the translational potential of the method.
WMC for use in whole-gut transit was validated using
dogs109 and has been used in several studies in dogs,110–112
pigs,113 rabbits,114 and horses.115 To our knowledge, vali-
dated technologies have not been developed for use in small
animals.
Evaluation of Colon Transit
Radiopaque Markers
Radiopaque markers can be used to evaluate total and
segmental colonic transit times. Several different methods
to measure colonic transit with radiopaque markers have
been described.116–120 The minimum number of markers to
be ingested daily should be at least 10–12 for reporting
colonic transit time in days or hours.121
Localization of retained markers in the rectosigmoid
area suggests functional outlet obstruction, whereas diffuse
distribution of the retained markers is suggestive of slow-
transit constipation. However, this is not diagnostic
because delayed rectosigmoid transit resulting from pelvic
ﬂoor dyssynergia may inhibit proximal colonic transit and
result in widespread distribution of markers.
Segmental transit times are measured in the right colon
to the right of the vertebral spinous processes and above a
line from the ﬁfth lumbar vertebra to the pelvic outlet. The
left colon is the area to the left of the vertebral spinous
processes and the line above the ﬁfth lumbar vertebra and
the left anterior superior iliac crest. The rectosigmoid is the
area under the line from the pelvic brim on the right to the
superior iliac crest on the left. The advantages of the radi-
opaque marker method are the well-established normal
values and standardization of methods, it also readily is
available and is reasonably inexpensive. Sadik et al120 have
quantitated rapid colonic transit using radiopaque markers.
Radiopaque markers are the reference standard for colon
transit evaluation in clinical practice.122
Colonic Scintigraphy
Measurement of colonic transit by scintigraphy is safe,
noninvasive, correlates with radiopaque markers, and pro-
vides information on ascending colon (AC) emptying and
overall colon transit.123 In the most widely published
method, subjects ingest a pH-sensitive methacrylate-coated
capsule containing indium-111–labeled activated charcoal
particles after fasting overnight, the coated capsule dis-
solves in the neutral pH in the terminal ileum, releasing the
radioisotope into the lumen.91 The alternative method fol-
lows the transit of radiolabeled liquid in a whole-gut transit
test for a solid–liquid meal including colonic transit.124
Repeated anterior and posterior abdominal scans of 2minutes’ duration acquired with a gamma camera at 4, 6, 8,
24, and 48 hours after ingestion to appraise colonic
transit125 were summarized as a geometric center
(weighted average) of radioactivity based on 5125 or 7
regions.124 The times of greatest interest for overall colonic
transit are at 24, 48, and 72 hours. The delayed-release
capsule facilitates the measurement of AC emptying as the
time for emptying half of the radioactivity from the AC,
which is calculated by linear interpolation of values on the
AC emptying curve.126 Thus, by delivering radiolabeled
charcoal particles to the ileocolonic region upon capsule
dissolution, the particles empty from the ileum into the
colon by bolus movements.127
Normal values, performance characteristics, coefﬁcients
of variation, application in patients with diarrhea or con-
stipation, differences in transit proﬁle between slow colonic
transit constipation and defecation disorders, and relation-
ship between colonic transit summaries at 24 and 48 hours
and bowel function symptoms have been documented
extensively.126,128–130
The intraindividual coefﬁcients of variation were 31% at
24 hours and 27% at 48 hours over a period of less than 3
weeks, and 38% at 24 hours and 30% at 48 hours over a
median interval of 2 years.126 The degree of variation is
similar across different mean values of colonic transit, and
the vast majority of individuals have replicate values within
1 geometric center unit of measurement. This variation re-
ﬂects the physiological, natural variation in stool frequency
and consistency.
Whole colonic scintigraphic transit and AC emptying
have been reported to be abnormal in several diseases of
colonic motility, including idiopathic constipation, functional
diarrhea, carcinoid diarrhea,131 and different subtypes of
irritable bowel syndrome132 and bile acid diarrhea. It
therefore is plausible that colonic transit measurement may
serve as a biological marker of colonic function in disease
and as a surrogate end point in the evaluation of drug
therapy.133 For example, scintigraphic colonic transit
correctly has predicted clinical efﬁcacy with medications
targeting different mechanisms, including prokinetics such
as 5-HT4 agonists, bisacodyl, and neurotrophin-3; medica-
tions retarding transit such as 5-hydroxytryptophan3
antagonists and cholecystokinin-1 antagonist; and secreta-
gogues such as linaclotide and lubiprostone. Equally
important, colonic transit measurement correctly has pre-
dicted a lack of efﬁcacy of medications to alter bowel
dysfunction in irritable bowel syndrome in clinical trials
when there were no signiﬁcant effects of the drug on colonic
transit, such as pexacerafont (corticotropin-releasing factor-
1 antagonist) and solabegron (b3 adrenergic agonist).Use of Wireless pH and Motility Capsule
to Measure Colonic Transit
The passage of the WMC into the cecum is determined by
the sudden decrease of pH by more than 1 U, which lasts for
at least 5 minutes; colonic transit time is the time from entry
into the cecum to the time the WMC passes out of the colon
with the sudden decrease in temperature and loss of
July 2016 Gastrointestinal and Colonic Motor Functions 419pressure recordings. Colonic transit time in 78 constipated
and 87 healthy subjects showed a median value of 21.7
hours (IQR, 15.5–37.3 h; 95th percentile, 59 h) in healthy
subjects and 46.7 hours (IQR, 24.0–91.9 h) in constipated
patients.134 The correlation of the WMC to the percentage
of radiopaque markers retained on day 5 was signiﬁcant
(r ¼ 0.69) in constipated patients studied simultaneously
with both methods.134
In a large multicenter study of 158 patients with con-
stipation, there was overall agreement of 87% for classi-
fying subjects as having slow or normal colonic transit.105
The WMC also has been used to characterize pressure ac-
tivity in colons of healthy controls and in constipated
patients.52
The advantages of the WMC assessment of colonic
transit are performance in the patients’ usual surroundings,
appraisal of whole gut and regional transit, and no radiation
exposure. Sometimes, discerning the 1-U decrease in pH
(entry into the cecum) may be difﬁcult. The method is more
expensive than other methods (radiopaque markers,
scintigraphy) to measure colonic or whole-gut transit.
Tests to Evaluate Gastrointestinal,
Colonic, and Anorectal Contractility
Antropyloroduodenal Manometry
The distal stomach, pylorus, and duodenum, with their
relatively small diameters and ability to generate high-
amplitude pressure activity, are suitable for manometric
recordings (Figure 2). Antroduodenal manometry is avail-
able mainly at a few tertiary referral centers; the test is
invasive, typically requiring tube placement with the aid of
upper gastrointestinal endoscopy, time consuming, and re-
quires skilled technical support. An alternative, a wireless
motility capsule, detects the frequency and amplitude of
phasic contractions during the process of capsule emptying
from the stomach and its passage through the small intes-
tine (and colon, see later).
The main indications for antroduodenal manometry are
as follows: evaluation of the cause of documented gastric or
small-bowel transit (neuropathy or myopathy) and clariﬁ-
cation of whether there is a generalized or localized dys-
motility in patients with suspected colonic inertia. The
method typically uses water-perfused manometric catheters
or solid-state sensors mounted on motility catheters. The
tube is positioned with the aid of ﬂuoroscopy. The intra-
gastric sensors should be 1 cm apart or less, to ensure
optimal measurements of distal antral contractile activity
proximal to the pylorus, which can be identiﬁed manomet-
rically by a combination of distal antral and duodenal peaks
and the presence of a high-pressure zone (tone). A solid-
liquid meal is ingested during the test, which predomi-
nantly appraises the amplitude of contractions and the
physiological responses in the fasting and postprandial
periods. Thus, normal gastroduodenal motility consists of at
least 1 MMC per 24 hours, conversion to the fed pattern
with ingestion of a meal without return of the MMC for at
least 2 hours after a meal of more than 400 kcal, and
consistent distal postprandial antral (>40 mm Hg, withan average frequency of 1 contraction/min during the
ﬁrst postprandial hour) and small intestinal contractions
(>20 mm Hg).135
Myopathic disorders (eg, scleroderma, amyloidosis, hol-
low visceral myopathy) are characterized by low-amplitude
contractions (consistently <20 mm Hg in the small bowel
and <40 mm Hg in the distal antrum).136 In neuropathic
disorders, there is increased frequency (eg, 3 during 3
hours) of fasting MMCs in the duodenum while awake,
postprandial antral hypomotility (average frequency of
contractions in distal antrum <1/min during the ﬁrst
postprandial hour), and a return of phase III MMC-like ac-
tivity within 2 hours of the ingestion of a meal of more than
400 kcal.137
Correlations of ﬁndings on manometry with histopa-
thology are poor, but they are based on a few detailed re-
ports138 of cases of pseudo-obstruction. Manometry has to
be interpreted with caution because abnormal motor pat-
terns do not necessarily imply causation of the patient’s
symptoms. Stress related to the intubation and procedure
may delay gastric emptying, impair antral contractility,
suppress MMC cycling, and induce intestinal irregularity.
The greatest use of gastroduodenal manometry in
research is in drug development, that is, in showing proki-
netic effects of novel medications in addition to effects on
gastric emptying, such as with the 5-HT4–receptor agonist,
cisapride,93 and the ghrelin-receptor pentapeptide agonist,
relamorelin.139Colonic Phasic Contractility and Tone
Tone is measured by the barostat, phasic contractions
can be measured by manometry or wireless pressure
capsule. Stationary laboratory-based studies to assess
motility usually are conducted for 6 hours, during which
colonic compliance, fasting, and 2-hour postprandial re-
cordings of contractions and tone are conducted. Ambula-
tory studies usually are conducted over 24 hours and
involve measurement of phasic contractions.140 There is
evidence that an increased number of solid-state sensors on
the colonic tube or a ﬁberoptic manometry catheter, pio-
neered by thorough and systematic research conducted
predominantly by Australian groups,141 results in high-
resolution measurements of antegrade and retrograde
contractions, as well as deﬁnition of the locus of origination
of high-amplitude propagated contractions.
In clinical practice, the main indications for colonic
manometry (usually with barostat assessment of compli-
ance and tone) are as follows: severe constipation with slow
colonic transit and no evidence of an evacuation disorder in
patients who are unresponsive to medical therapy,142 and
conﬁrmation of chronic megacolon or megarectum
(Figure 3) when viscus diameters exceed 10 and 15 cm,
respectively.143 The most useful measurements in research
and clinical practice are compliance142,143 and high-
amplitude propagated contractions,144 and the responses
to intravenous neostigmine.145 The reproducibility and
performance characteristics of compliance and tone mea-
surements have been documented in the literature.146
Figure 2. Antroduodenal
motility tracings in the
postprandial period with
sensors 1-cm apart. Note
in the upper example the
consistent phasic and
tonic contractions at the
pylorus with intermittent
loss of distal antral con-
tractions 1 and 2 cm
proximal to the pylorus.
In contrast, note the
consistent antropyloric
coordination in the
normal example in the
lower tracings. Repro-
duced with permission
from Camilleri.185
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to show the effects of biological agents (eg, bile acids),147
pharmacologic agents (eg, cholinergic modulation as with
neostigmine),148 adrenergic agents,149 cannabinoid-
receptor agonist,150 ghrelin-receptor agonist,151 and
5-HT4–receptor agonist.
152
Colonic measurement of contractions has been used in
several preclinical models recorded by surgically implanted
strain-gauge transducers. For example, Briejer et al153
showed induction of giant migrating contractions by pru-
calopride in the dog, and Sarna et al154 examined several
neurotransmitter substances that modulate contractile ac-
tivity of the rat colon. High-resolution manometry has
advanced rapidly and may become a preclinical model of
choice.155
Similarly, measurement of colonic tone, compliance and
reﬂexes, and responses to meals and pharmacologic agents
have been measured in the canine colon, into which a
barostat device was inserted, typically through a cecal
cannula.156–158 More recently, barostat studies of the colon
have been performed in the horse159 and pig.160Anorectal Manometry
Anorectal manometry is essential for the evaluation of
patients with constipation (to exclude evacuation disorders)or fecal incontinence.155 Two technologies that currently
dominate in practice and research161–163 are as follows.
First, high-resolution anorectal manometry (HRAM) with
ﬂexible catheters, typically with 8–12 longitudinal sensors
spaced approximately 0.6- to 1-cm apart, and the most
proximal 1 or 2 sensors within a balloon attached to the
uppermost part of the catheter for rectal distension/sensory
testing, and the most distal sensor, left outside of the
anal canal, recording atmospheric pressure. Other conﬁgu-
rations use 12–36 circumferential sensors or 4 radially ar-
ranged sensors at each level, from which pressures can be
averaged to provide a mean pressure. Second, 3-
dimensional high-deﬁnition anorectal pressure manom-
etry/topography (3-D HDAM), which uses a rigid probe
(100-mm length and 10.75-mm diameter) housing 256
pressure sensors arranged in 16 rows spaced 4-mm apart,
each containing 16 circumferentially oriented sensors 2.1-
mm apart). The area of measurement is 6.4-cm long and
provides detailed anal morphology by linear interpolation
through dedicated software to provide 2-dimensional or 3-D
cylindric topography of the anal canal, which can be viewed
from all sides.
Normal values that are inﬂuenced by age, sex, and body
mass index have been published. In general, there is
reasonable concordance between studies of average values
reported for anal resting tone, although resting tone and
Figure 3. Colonic compli-
ance in (A) healthy, (B)
functional constipation/
constipation-predominant
irritable bowel syndrome,
(C) diarrhea-predominant
irritable bowel syndrome
(IBS-D) groups; and (D)
patients with chronic
megacolon. Note the
markedly increased volume
of the intracolonic balloon
(10-cm long) inpatientswith
megacolon compared with
controls. Reprinted with
permission from O’Dwyer
et al.143
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with HRAM/3-D HDAM techniques, possibly owing to
reduced ﬁdelity of traditional water-perfused systems.
Further studies are required to validate the utility of HRAM/
3-D HDAM techniques for evaluating and diagnosing dys-
synergia in patients with defecatory disorders and fecal
incontinence.155,164
Anorectal manometry studies are applied less often in
research studies other than for the assessment of different
methods for normalizing functions in defecatory disorders
or fecal incontinence.165
Colonic Motility and Transit
in Preclinical Studies
Bead expulsion assays in mice have become the pre-
clinical model of choice to understand effects on colonic
motility.166,167 The assay involves the intrarectal insertion
of a 2- to 3-cm glass bead within the colon in awake mice
and measurement of the time it takes for the bead to leave
the anus. There is tremendous variability in the assay both
between and within individual animals. This variability
likely is owing to stress-induced defecation in mice in which
5–6 fecal pellets, the entire content of the mouse colon, are
expelled at once.
Colonic motor activity in mice also has been assessed
using water-based168 and solid-state manometers.169
Although these measures of pressure improve the ability
to assess colonic motility beyond the limits of bead expul-
sion assays, they remain isolated measures of contractility.
The development of dual-sensor manometric probes170 toassess propulsive and retropulsive contractions in mouse
colon provides hope that more advanced technologies for
mouse colonic motility are forthcoming.
Scintigraphy and manometry have been used to study
colonic motility in rats.170–174 In addition, the defecation
reﬂex has been well characterized in rats, making this ani-
mal model suitable to replace dogs for preclinical testing.175
Fluoroscopic analysis of colonic motility has been studied
extensively in the pig.176 Although pigs typically are not
used in drug discovery, the pig has been developed as a
preclinical model of electrical stimulation for evacuation
dysfunction and manometry to assess contractility.177
Colonic motility in the rabbit also has been characterized
radiographically,178 and recent advances in high-resolution
colonic manometry are being validated using rabbit co-
lon,179 which may make rabbits a preclinical animal of
choice in the near future.
New MRI Parameters of
Gastrointestinal Function
MRI applications have been proposed to measure several
gastrointestinal functions: gastric volumes and emptying;
small-bowel water content; colonic volumes; bowel gas
volumes; esophageal, gastric, small-bowel, and colonic
motility; anorectal and pelvic ﬂoor motion and anatomic
integrity; and whole-gut transit measured using MRI
capsule markers ﬁlled with watery gel pellets or water
labeled with an MRI contrast agent. These methods have
been reviewed in detail elsewhere.180 It is interesting to
note that software-quantiﬁed bowel motility using cine MRI
422 Camilleri and Linden Cellular and Molecular Gastroenterology and Hepatology Vol. 2, No. 4has potential as a future tool to investigate enteric dysmo-
tility, using a validated motility assessment technique based
on motion-capture MRI.101 Another application of MRI to
measure colonic motility involves challenge with a laxative
preparation (polyethylene glycol 3350 electrolyte solution)
and use of MRI marker pills.181
Conclusions
There have been numerous recent advances in mea-
surement of gastrointestinal motility in both human and
preclinical models. Imaging technologies especially have
advanced rapidly, and it is encouraging to recognize that
digestive disease researchers appear to be keeping pace
with these advances. It is instructive to understand that, just
as the invention of the Roentgen tube in 1895 was adapted
rapidly by Cannon182,183 to make the ﬁrst seminal obser-
vations of modern gastrointestinal motility and formed the
basis for the modern scintigraphic tests presented here,184
modern neurogastroenterologists rapidly are adapting
other medical imaging technologies and high-resolution or
ﬁberoptic measurements of intraluminal pressures into
novel clinical tests. It also is important to recognize the
value of reverse translating new clinical tests for use in
preclinical studies. Nowhere is this idea better shown than
the reverse translation of gastric emptying tests for use in
mice. It is our sincere hope that the juxtaposition of state-of-
the-art motility tests for both human beings and animals
will inform researchers of the great potential of this
bedside-to-bench-to-bedside approach for the future of
neurogastroenterology.References
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